Aceon Gets Coronary Artery Disease Approval Ahead Of Schedule
This article was originally published in The Pink Sheet Daily
Executive Summary
Aceon adds indication for reduction of risk of cardiovascular mortality and non-fatal myocardial infarction in patients with stable coronary artery disease ahead of Sept. 10 user fee date.